Ocular Therapeutix Reports Positive Pre-NDA Meeting With FDA For AXPAXLI In Wet AMD

Ocular Therapeutix completed a Pre-New Drug Application meeting with the FDA for AXPAXLI, its investigational treatment for wet age-related macular degeneration. The regulatory interaction is a positive step toward a potential NDA submission, but the article provides no approval decision, clinical data, or financial guidance.